argenx SE (MEX:ARGXN) Research & Development: MXN27,340 Mil (TTM As of Mar. 2026)


MEX:ARGXN argenx SE MEX:ARGXN
63 GF Score
Price MXN13,000.67
GF Value MXN20,951.12
! 5 Warning Signs
View Full Analysis

What is argenx SE Research & Development?

argenx SE MEX:ARGXN 63 Research & Development is MXN27,340 Mil as of Mar. 2026. GuruFocus rates MEX:ARGXN with a GF Score™ of 63/100 and a GF Value™ of MXN20,951.12. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. argenx SE's Research & Development for the three months ended in Mar. 2026 was MXN7,988 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN27,340 Mil.

argenx SE  (MEX:ARGXN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

argenx SE Research & Development Related Terms

argenx SE Research & Development Historical Data

* Premium members only.

The historical data trend for argenx SE's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Research & Development Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,908.79 12,932.98 14,589.23 20,509.98 24,562.15

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,362.50 6,133.93 6,524.13 6,692.97 7,988.49
MEX:ARGXN
63GF Score
argenx SE MEX:ARGXN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN27,340 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN27,340 Mil mean?
argenx SE (MEX:ARGXN) has a Research & Development of MXN27,340 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on argenx SE and its competitors.
Is argenx SE's Research & Development too high?
argenx SE's current Research & Development is MXN27,340 Mil. Overall, argenx SE has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Research & Development compare to VRTX and REGN?
argenx SE's Research & Development of MXN27,340 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on argenx SE and its competitors. argenx SE's current Research & Development is MXN27,340 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
argenx SE (MEX:ARGXN) has a current Research & Development of MXN27,340 Mil. The stock's GF Value™ is MXN20,951.12, compared to a current price of MXN13,000.67 — trading 37.9% below its estimated fair value. The current Research & Development is MXN27,340 Mil. argenx SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For argenx SE (MEX:ARGXN), the current Research & Development is MXN27,340 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (MEX:ARGXN) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of MXN13,000.67 is trading 37.9% below its estimated GF Value™ of MXN20,951.12.

Key valuation signals for MEX:ARGXN:

  • Research & Development: MXN27,340 Mil
  • GF Value™: MXN20,951.12 vs. price of MXN13,000.67 (37.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
63GF Score

Get the complete analysis for MEX:ARGXN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN13,000.67
Price
MXN20,951.12
GF Value